Researchers from The University of Osaka identify a molecule that can support specific therapeutic targeting of AML with ...

The FDA granted a positive review for an acute myeloid leukemia drug trial, with initial dosing expected in 2025.

After his passing, the family started the Timothy O’Connell Foundation, raising more than a million dollars for research, ...

It is indicated for patients with a susceptible IDH1 mutation, which is identified through an FDA-approved test. Currently, ...

About 6% of pregnancy-related cancers are Hodgkin lymphoma, and 5% are non-Hodgkin lymphoma. Leukemias in pregnancy are rarer ...

Ziftomenib’s FDA application for relapsed/refractory NPM1-mutant acute myeloid leukemia is supported by data from the ...

SLS009 is associated with an improvement in survival among patients with relapsed/refractory acute myeloid leukemia.

Kura Oncology, Inc. (Nasdaq: KURA, "Kura"), and Kyowa Kirin Co., Ltd. (TSE: 4151, "Kyowa Kirin"), today announced Kura submitted a New Drug Application ...

Ziftomenib has received Breakthrough Therapy, Fast Track, and Orphan Drug Designations. The FDA has a 60-day filing review period to determine whether the NDA is complete and accepted for review; Kura ...

Kura Oncology (KURA) announced Kura submitted a New Drug Application for ziftomenib, a highly selective, once-daily, oral, investigational ...

Athletic’ woman given months to live after headaches dismissed as ‘long Covid’ - The 33-year-old started noticing something ...